Citryll

Citryll company information, Employees & Contact Information

Explore related pages

Related company profiles:

Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm.

Company Details

Employees
32
Founded
-
Address
Oss, Noord-Brabant 5349 Ae , Nl
Email
in****@****yll.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Oss, Noord-Brabant
Looking for a particular Citryll employee's phone or email?

Citryll Questions

News

Citryll Presents Positive Data from Phase I Study of CIT-013 in Rheumatoid Arthritis at ACR Convergence 2025 - Yahoo! Finance UK

Citryll Presents Positive Data from Phase I Study of CIT-013 in Rheumatoid Arthritis at ACR Convergence 2025 Yahoo! Finance UK

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS - Yahoo Finance

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS Yahoo Finance

Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders - GlobeNewswire

Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders GlobeNewswire

Inhibition of EETosis with an anti-citrullinated histone antibody: a novel therapeutic approach for eosinophilic inflammatory disorders - Frontiers

Inhibition of EETosis with an anti-citrullinated histone antibody: a novel therapeutic approach for eosinophilic inflammatory disorders Frontiers

Citryll doses first subject in Phase IIa trial of monoclonal antibody for RA - Clinical Trials Arena

Citryll doses first subject in Phase IIa trial of monoclonal antibody for RA Clinical Trials Arena

Citryll Raises EUR 85 Million Series B to Advance Novel - GlobeNewswire

Citryll Raises EUR 85 Million Series B to Advance Novel GlobeNewswire

Citryll BV raises €85m in Series B financing - European Biotechnology Magazine

Citryll BV raises €85m in Series B financing European Biotechnology Magazine

Anti-citrullinated histone monoclonal antibody CIT-013, a dual action therapeutic for neutrophil extracellular trap-associated autoimmune diseases - Taylor & Francis Online

Anti-citrullinated histone monoclonal antibody CIT-013, a dual action therapeutic for neutrophil extracellular trap-associated autoimmune diseases Taylor & Francis Online

Oss-based Citryll secures €85 million Series B funding to advance NET-targeting therapy - EU-Startups

Oss-based Citryll secures €85 million Series B funding to advance NET-targeting therapy EU-Startups

Citryll raises 85 million euros - The Pharma Letter

Citryll raises 85 million euros The Pharma Letter

Citryll concludes subject dosing in Phase I trial of CIT-013 - Clinical Trials Arena

Citryll concludes subject dosing in Phase I trial of CIT-013 Clinical Trials Arena

Dutch Antibodies for Autoimmune Diseases Boosted by €15M Series A - Labiotech.eu

Dutch Antibodies for Autoimmune Diseases Boosted by €15M Series A Labiotech.eu

Top Citryll Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant